Esperion Therapeutics Inc. (NASDAQ:ESPR) has reported a significant surge in its first-quarter revenue for 2024, with a total revenue of $137.7 million. This figure includes a substantial $100 million from a litigation-related settlement. The company's U.S. net revenue saw a 46% increase compared to the previous year, amounting to $24.8 million.
This financial growth coincides with the FDA's approval for expanded labels for Esperion's drugs, NEXLETOL and NEXLIZET, which are now uniquely positioned as the only non-statins approved for cardiovascular risk reduction in patients. The company is also advancing its commercial and manufacturing strategies to further strengthen its market position.
Key Takeaways
- Esperion's total revenue reached $137.7 million in Q1 of 2024, a 467% increase year-over-year, partly due to a $100 million settlement.
- U.S. net revenue grew by 46% year-over-year to $24.8 million.
- FDA approval for expanded labels of NEXLETOL and NEXLIZET has positioned them as preferred non-statin treatments for cardiovascular risk.
- The company has begun the tech transfer process for manufacturing in Europe with partner DSE.
- Esperion launched commercialization initiatives, including a consumer campaign and updated promotional tools.
- The company reported a strong balance sheet with $226.6 million in cash and cash equivalents.
- R&D expenses decreased by 57% year-over-year, while SG&A expenses rose by 40%.
- Esperion expects increased prescribing from primary care and positive payer discussions to drive growth.
Company Outlook
- The company reaffirms its 2024 expense guidance, indicating confidence in its financial strategy.
- Esperion anticipates ongoing alignment with new drug labels by additional payers, supporting future revenue growth.
Bearish Highlights
- The company's R&D expenses have seen a significant decrease, which could raise questions about future innovation and product pipeline.
Bullish Highlights
- The approval of expanded drug labels and the initiation of the tech transfer for European manufacturing are expected to bolster market presence and revenue.
- The company's commercial initiatives and consumer campaigns are likely to enhance product uptake and brand recognition.
Misses
- There were no specific misses reported in the earnings call.
Q&A Highlights
- Esperion clarified that stocking and inventory build did not impact quarterly revenue.
- The company expects gross to net trends to follow historical patterns, with no significant changes anticipated from payer requests or concessions.
- Positive interactions with payers regarding the updated drug labels were reported, with no pushback encountered.
Esperion's first quarter of 2024 has set a promising tone for the year, with substantial revenue growth and strategic FDA approvals that may reshape the cardiovascular treatment landscape. The company's financial health is solid, with a strong balance sheet and reiteration of its expense guidance, suggesting a stable outlook.
Esperion's proactive approach to commercialization and payer engagement is expected to drive prescription growth and support its position in the competitive pharmaceutical market.
InvestingPro Insights
Esperion Therapeutics Inc. (ESPR) has shown a remarkable revenue growth in the last twelve months as of Q4 2023, with a 54.14% increase, including a quarterly surge of 71.38%. This performance reflects the company's successful commercial strategies and the recent FDA approvals. InvestingPro data indicates that Esperion has a market capitalization of $450.77 million, underscoring its significant presence in the pharmaceutical sector despite the lack of profitability in the recent past.
InvestingPro Tips reveal that analysts are optimistic about Esperion's sales growth in the current year, which aligns with the company's robust first-quarter revenue report for 2024. On the other hand, the company's gross profit margins have been weak, with a gross profit margin of -11.21% for the last twelve months as of Q4 2023. This could be a point of concern for investors considering the company's cost management and profitability.
Esperion's stock has seen a significant return over the last week with a 7.61% increase, yet it has experienced a decline over the last month. The six-month return, however, is impressive at 105.83%, reflecting a large price uptick during this period. These metrics suggest a volatile stock performance, which could be indicative of the market's reaction to both the company's achievements and its challenges.
For investors looking for more in-depth analysis, there are additional InvestingPro Tips available to help navigate Esperion's financial landscape. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and gain access to valuable insights that could inform your investment decisions. Visit https://www.investing.com/pro/ESPR for further information and to discover the full range of tips, including Esperion's profitability outlook and dividend policy.
Full transcript - Esperion Therapeutics Inc (ESPR) Q1 2024:
Operator: Ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question-and-answer session. Please be advised that today's conference call may be recorded. I would now like to hand the conference over to Tiffany Aldrich, Associate Director of Corporate Communications at Esperion. Please go ahead.
Tiffany Aldrich: Thank you, operator. Good morning and welcome to Esperion's first quarter 2024 earnings conference call. With us today are Sheldon Koenig, President and CEO; and Ben Halladay, CFO. Other members of the executive team will be available for Q&A following our prepared remarks. We issued a press release earlier this morning detailing the content of today's call. A copy of that release can be found on the Investor page of our website together with a copy of the presentation that we will also be referencing. I want to remind callers that the information discussed on the call today is covered under the Safe Harbor provision of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and in our SEC filings. The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 7, 2024. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast. As a reminder, this conference call and webcast are being recorded and archived. We will begin the call with prepared remarks and then open the line for your questions. I'll now turn the call over to Sheldon.
Sheldon Koenig: Thank you, Tiffany and good morning everyone. Thank you for joining us today to discuss our first quarter results and the meaningful progress we continue to make. We are proud to report that we drove strong growth this quarter to start 2024, positioning us for long-term growth and success. In the first quarter, we delivered total revenue of $137.7 million. which includes the $100 million litigation-related settlement received from DSE in January. I'll note that even excluding this payment, this was the highest revenue-generating quarter for ongoing business in our company's history. U.S. net revenue was $24.8 million, which represents a 46% increase year-over-year, driven by a 43% increase in retail prescription equivalents. On March 22nd, we received FDA approval of broad new labels for NEXLETOL and NEXLIZET that reflect new indications for cardiovascular risk reduction and expanded LDL-cholesterol lowering in both primary and secondary prevention patients. These new labels make NEXLETOL and NEXLIZET the only LDL-lowering non-statins approved for cardiovascular risk reduction in both primary and secondary prevention patients and can now be taken with or without a statin. With these differentiated profiles, we are confident that these new labels position NEXLETOL and NEXLIZET as the non-statins of first choice in treating patients with or at risk for cardiovascular disease. These new labels are also significant in their ability to bridge what we call the statin gap, which encompasses the tens of millions of patients at risk for cardiovascular disease who are unable or unwilling to take recommended statin therapy. These approvals expand our potential addressable population to more than 70 million patients in the U.S. alone. The FDA approvals came on the heels of a positive CHMP opinion and we continue to anticipate a similar and positive decision from the European Commission based on the EMA assessment on our European cardiovascular risk reduction label submissions by the end of the second quarter 2024. And on the topic of ex-U.S. progress, I'll note that we have initiated the tech transfer process with our partner DSE for the manufacturing and supply of our tablets in Europe and we expect that process to be complete in the second half of next year. Ahead of the highly anticipated FDA approvals, we were preparing on all fronts to be ready to capitalize on our new label the moment we have them and we have hit the ground running. I'm pleased to share that all commercialization initiatives that we've previously mentioned are now in place. We launched our lipid lurkers consumer campaign and promotional digital tools. Our field teams have been fully trained and certified on our new indications and resources and participated in an in-person launch meeting last month. We initiated partnerships to bolster our patient services platform to ensure health care practitioners can prescribe for appropriate patients, while we await payer utilization management criteria changes which usually take one to two quarters. On that note, I am pleased to share that we recently received confirmation of utilization management updates aligning to our new label from two large payers, one commercial payer with 23 million lives that will reflect the new label June 1, and two of the largest Medicare payers that represent eight million and nine million lives each, immediately updated within a week of the label change. We anticipate additional payers to align with our new labels on an ongoing weekly basis. In summary, we've made significant progress and while it's still early we're encouraged by the positive initial momentum we've seen thus far in the first weeks of the second quarter. With that, I will now hand it over to Ben for a more detailed review of our first quarter financial performance.
Ben Halladay: Thank you, Sheldon. Earlier this morning, we issued a press release containing our financial results for the first quarter, which is available on the Investor page of our website. Please note that unless otherwise specified my comments reflect results for the first quarter ended March 31, 2024. As Sheldon mentioned, we are proud of our performance and strong results we delivered in the first quarter including new-to-brand prescription. Our momentum continues to accelerate which underscores the fact that outcomes data matters and we're thrilled that data is now incorporated into our new label, which means we can now actively promote that data for the first time and that we'll now be able to reach millions more patients in need. For the fifth quarter in a row, we again delivered continued growth in retail prescription equivalents which increased 43% year-over-year and 6% quarter-over-quarter. And as a reminder almost entirely dependent on our prior label and promotional footprint that has only recently ramped up. The weekly RPE trend again reflects this momentum and remained above the 12,000 RPE mark for all of March a new high for us. Growth outside the US also continued at an impressive clip. Our partner DSE delivered yet another strong quarter of sales growth in its territory, highlighting the value and growth of potential of our global franchise. At the end of February, approximately 255,000 patients have now been treated with our therapies in Europe representing a sequential three month growth of 26% since November. While most of this growth was generated from existing territories DSE continues to expand launching in the Czech Republic in the first quarter. I'll also note progress by our Asia region partner Daiichi Sankyo Companies Limited which gained approvals in Myanmar and Thailand in the first quarter. Turning to our financial results for the quarter. We reported US net product revenue of $24.8 million representing an increase of 46% year-over-year. Collaboration revenue which includes combined royalty and partner revenue was $113 million, an increase of 1,148% year-over-year. This growth includes the $100 million settlement received in January in connection with our litigation revolution, excluding milestone payments combined royalty and partner revenue grew 110% year-over-year. Finally, total revenue for the first quarter was $137.7 million, an increase of 467% year-over-year. I'll note that this includes the previously mentioned $100 million settlement excluding milestones total revenue grew 65% year-over-year. Turning to expenses. Cost of goods sold for the first quarter was $10.1 million, a decrease of 14% year-over-year driven primarily by lower unit tablet costs for sales in the US and supply to our international partners. R&D expense was $13.4 million, a decrease of 57% year-over-year reflecting substantially lower costs following the closeout of our CLEAR Outcomes trial. SG&A expense was $42 million an increase of 40% year-over-year reflecting higher head count as we began to ramp up our in-house sales force bonuses and promotional costs in anticipation of the launch of the expanded labels from NEXLETOL and NEXLIZET. Finally, cash and cash equivalents totaled $226.6 million as of March 31, 2024 compared with $82.2 million on December 31, 2023 reflecting a strong balance sheet with sufficient capital to support our commercial operations and drive continued long-term growth. We also reiterate our 2024 expense guidance continuing to expect R&D expense to be between $45 million and $55 million SG&A expense to be between $180 million and $190 million and total OpEx expense to be between $225 million and $245 million. Although, we've meaningfully strengthened our balance sheet in the first quarter we will continue to remain disciplined with expense management ensuring sufficient returns are being generated across the company. And with that let me now hand it back over to you, Sheldon.
Sheldon Koenig: Thank you, Ben. In closing, we continue to deliver on our commitments and execute on our strategic plan to achieve the blockbuster status who we know our franchise is capable of. We delivered another strong quarter of growth and ended the quarter with sufficient capital to support our commercial initiatives and drive continued long-term growth. We received approval for broad new labels and launched commercial initiatives to capitalize on the opportunity we now have to reach the millions of patients in need of our therapies. In summary, I remain extremely confident that we will continue to drive patient and shareholder impact and value creation by capitalizing on this momentum throughout this year and into the future, and I thank the entire Esperion team for helping us get to this pivotal moment. Operator, we are now ready for Q&A.
Operator: Thank you. [Operator Instructions] Our first question comes from the line of Dennis Ding with Jefferies. Your line is open.
Dennis Ding: Hi. Good morning and thanks for taking our questions. Two for me. Maybe one on the -- if you guys can just comment on the prescription habits from doctors since the label update. Have you seen any shift in PCPs versus cardiologists that you want to call on and if you're seeing any enthusiasm among the primary prevention doctors? And secondly the on scripts they've kind of look generally flat since the label update. So I'm just wondering if you have a comment on what happened over the last month? And when do you expect that script -- the weekly script growth to reaccelerate? Thank you.
Eric Warren: And hi, Dennis, it's Eric. I'll take this one. So, first of all, yes, there's a lot of enthusiasm for the new label. And that primary prevention is generating a lot of enthusiasm as well. Just a reminder that we are the only non-statin that's FDA approved to lower LDL-C and to decrease the risk of MI and coronary revasc in those primary prevention as well as secondary prevention patients. So enthusiasm is strong. We see right now a balanced prescribing between primary care and then cardiologists, but I expect that primary care prescribing to increase. And remember it's about utilization management criteria as well. So those progressive increases that we'll see as payers start to enable prescribing for those populations. I'm encouraged by the early qualitative feedback. And then the last two weeks as you've probably seen we have seen week-over-week growth. So expected to take a little bit of time but expect progressive increases again as those payer changes increase but customer enthusiasm is incredibly high.
Sheldon Koenig: And Dennis, I just wanted to add that we're super early in the game. Our representatives were trained on the label actually received the first view of the label early April. And then they're essentially off territory for two weeks in April because we had an all-company meeting, we also had our training, and they actually received the full detail aid in the third week of April. They were detailing off of the label. So just to reiterate what Eric is saying, we're actually very encouraged in what we're seeing right now. And as we said in our prepared remarks, we're very confident about growth as we continue through the quarters.
Dennis Ding: Got it. And then maybe if I can follow-up. In terms of the script re-acceleration around when do you expect that to curve? Because when you look at the last two weeks, they have been growing 1% to 5%, but I'm just wondering if that could grow more and when the soonest that could happen? Thanks.
Eric Warren: Yes, Dennis, so again, progressive increases are what I would anticipate. And it really will be as the bulk of utilization management changes. We anticipate about two quarters to get the majority of UM aligned with the new label. So progressive increases with full growth realization when we have that UM alignment.
Dennis Ding: Got it. Thanks and congrats on the progress.
Eric Warren: Thanks, Dennis
Operator: Thank you. Please standby for our next question. Our next question comes from the line of Serge Belanger with Needham. Your line is open.
Serge Belanger: Hi, good morning. Thanks for taking my questions. First one, as the utilization management gets updated across the payers with the new label. Can you just remind us what it's going to look like and whether you expect it to be pretty standard across all the payers covering bempedoic acid? And secondly, I think Medicare coverage for the product has lagged the commercial coverage. Can you just give us an update on when you expect Medicare coverage to pick up on the product? Thanks.
Eric Warren: Yes. Thanks, Serge. So as you're aware and as we've stated in the past that the prior utilization management criteria has required patients to have ASCVD or be a secondary prevention patient. When the utilization management changes start to happen, we will see the primary prevention patients included as well. We've also had pretty significant statin requirements or maximally tolerated statin requirements that we anticipate to ease as well based upon the outstanding new label that we have. With regards to Medicare as Sheldon mentioned in the opening remarks, we did see already a Medicare payer change and update their utilization management criteria. And there will be many more of those on the horizon over the course of the next two quarters. So very encouraging. And hopefully that answers your question, Serge.
Sheldon Koenig: Eric, if I could just add. This was a new -- so we had one that updated the UM criteria and then we had one that is one of the largest Medicare providers. That was an absolute new win. So it gets our coverage closer to 50% in Medicare. So we're very happy about that.
Serge Belanger: Great. And then maybe just one follow-up. So as the Medicare coverage ramps up, do you expect any impact to gross to net going forward?
Ben Halladay: Hey, Serge this is Ben. I'll take that. Not a meaningful one. I would say Medicare coverage gap is always something that affects us it has in the past. But I think as a sort of distribution of the total, it's not going to be a meaningful impact to gross than that.
Serge Belanger: Thank you.
Operator: Thank you. Please standby for our next question. Our next question comes from the line of Tom Shrader with BTIG. Your line is open.
Tom Shrader: Good morning. Congratulations. It looks like we're close now. So I had a very general question. You're in the market with a statin alternative, I think we all use this vague number of 10% of patients have some troubled statins. Do you have updates on that number? Are you finding that that number is close or very off or -- and does it differ between under-treated and treated patients? I'm just wondering if we could borrow some of your market surveillance. Thank you.
JoAnne Foody: So Tom this is JoAnne Foody. From the standpoint of statin intolerance, I think what we're understanding is that statin intolerance is a broad range. So your 10% number may speak to individuals who are completely unable or unwilling to take a statin. When we look at the opportunity for our therapy, it is in individuals who can't take a statin at all, right, which has that kind of number of 10%. But in fact in individuals who can't escalate their dose of a statin, lower dose to maximally tolerated and those taken together start to get its numbers closer to the 30%. I can't speak to the market. Eric if you'd like to speak to that that's fine. But from a clinical perspective, the numbers are closer and we'll be publishing data and have published data in that realm showing that it's probably closer to 30% if we think about complete and partial statin intolerance.
Eric Warren: And that's part of our education process Tom, as well as to let HCPs know that statin intolerance isn't just the inability to take any statin, but it is that inability to maximize statin doses. And that's something that HCPs have been very receptive of -- it brings the bell as they're starting to think of patients. And as we go out and communicate appropriate patients, that is definitely a patient that we're focused on.
Tom Shrader: And just a quick follow-up. So, we as under-treated the bigger opportunity because they're clearly under the care of a physician and know their lipid numbers?
Eric Warren: Yeah. It's -- I mean, there's clearly a recognition that patients can't achieve their goals with current therapies. So those that are actively treating our primary focus. As we've said, there is roughly a 70 million eligible patient population as a result of our label change. We're focused on 30 million of those patients, and those are patients that are actively engaged in therapy.
Tom Shrader: Perfect. Good. Thank you.
Eric Warren: You're welcome.
Operator: Thank you. Please standby for our next question. Our next question comes from the line of Jessica Fye with JPMorgan (NYSE:JPM). Your line is open.
Jessica Fye: Hey, guys. Good morning. Thanks for taking my question. I wanted to ask about volume trends we saw a clear inflection in volume on the back of ACC last year, and we're sort of just starting to annualize over that, albeit with the approval now in hand. So should we expect another inflection in volume, thanks to the ability to promote or maybe more of a continuation of the trajectory the franchise has been on? Or is it reasonable to think about a deceleration given just the tougher comps? Maybe I'll stop there.
Sheldon Koenig: Hey, Jess. I'll start with this. So we've always said that with our label, you would see a meaningful inflection of our business. Even before our label, we said that, we would show continued quarterly growth. Again, keep in mind, in the first quarter, the results that we're showing today, it doesn't even include what we didn't have the new label yet. So I think if I understand your question correctly, the outlook is, we will continue to show acceleration in the growth of our products based upon the new label just previously mentioned, we know that we have a patient population of close to 70 million patients who could benefit from this drug in additional LDL lowering and risk reduction. What we haven't talked about is the actual pace of that growth. It's not going to happen as a quick inflection, but we're going to see meaningful growth, more aggressive growth as we march through the quarters.
Jessica Fye: Great. Thank you.
Operator: Thank you. Please standby for our next question. Our next question comes from the line of Jason Butler with Citizens JMP. Your line is open.
Unidentified Analyst: Hi. Good morning. Thanks for taking the question. This is Josef [ph] for Jason. Just a very quick from us. Have any of the payers push back an increase in access following the label expansion?
Eric Warren: Yeah, it's Eric, I can start this one off. So I'd say, our discussions have been very positive so far. I haven't heard of any negative receptivity from a payer perspective. Obviously, payers have their own time lines, so some of them may operate sooner than others. But based upon the cadence of how this was handled, initially, there were medical discussions and then those translated into confirmation post label change and then business discussions. And so far, all these discussions have been very favorable.
Unidentified Analyst: Very helpful. Thanks. And just a very quick one on the commercial effort. So now that all the commercial efforts are placed, how are you gaining success of the commercial investment in the US? And do you expect to make any adjustment to the sales force accordingly?
Eric Warren: Yes. So we've made the adjustments to the sales force. So we're at the number that we anticipate staying at for a while which is at 150. As a reminder, with the sales force or personal promotion, as well as our digital footprint, we're able to cover about 45,000 HCPs. So we've got a good infrastructure in place in terms of how do we measure success? Well, first of all we have to have discussions with our HCPs. So we're looking at both the commercial the – actually the digital reach as well as the personal reach. And our teams have been very successful in having those discussions with the targeted HCPs. The digital footprint has been strong, we've seen over 19 million impressions between HCPs and consumers over the first five weeks. So those are very encouraging metrics. So obviously, those are some early indicators. But the significant indicators will be actually watching those share increases happen over the upcoming weeks and quarters.
Unidentified Analyst: Very helpful. Thanks for taking the questions.
Eric Warren: You’re welcome.
Operator: Thank you. Please stand-by for our next question. Our next question comes from the line of Joe Pantginis with H.C. Wainwright. Your line is open.
Joe Pantginis: Hey, everybody. Good morning. Thanks for taking the questions. So I wanted to approach the question also from the statin intolerance or long-term side effects and sort of overall concern from some patients in general, where right now all the focus is on HCPs and their views about the new label and we're expecting to see that growth inflection as you guys are as well. So I guess I would ask the question from the following standpoint. Are you going to collect data? Or do you even want to sort of pontificate if you will about the role of patients in helping to drive those decisions. As you know, they're much more savvy. They have Google (NASDAQ:GOOGL) and what have you or they're saying "I haven't had an option for a statin up to this point doctor but this really looks interesting". How – what role do you think patients' feedback will have in changing their treatment guidelines?
Eric Warren: It's going to have a significant role Joe. So as Sheldon mentioned in the opening remarks, we do have a consumer base campaign that we've deployed as well. We call these little creatures the lipid lurkers and they're out there. They're present raking havoc. And we've put those forward in the digital universe. Just from a meta campaign perspective, we've seen 1.6 million exposures with the lipid lurkers and they're present in many other platforms as well. So consumers play a significant role. Obviously, we've got to be very targeted. We don't want to go to the broad consumer universe. We want to go to those who are target patient. And I think the team has done a great job so far at doing just that.
Sheldon Koenig: And Joe, just – first of all, good morning. What we saw last year or two after ACC and we did collect data is that consumers really went out there. When they saw information, et cetera to your point, consumers are very different. They're well informed now. They want to find out more. And we saw a lot of them post ACC head out into their physicians' offices and ask about NEXLIZET NEXLETOL we recently received some research, which shows that they're doing it again. Eric and I were just mentioning when we were in the office that, even on our Instagram or Facebook (NASDAQ:META) we're seeing these Lipid Lurkers and we're also seeing the new campaign that we have. So, it's definitely a big part of it. And people want to know about one, I have to -- I don't want to take a stronger dose of a statin or I don't want to take a statin, because I can't. So they're very savvy about this.
Q – Joe Pantginis: No, I appreciate that color. Thank you very much.
Sheldon Koenig: Thank you, Joe.
Operator: Please standby for our next question. Our next question comes from Jason Zemansky with Bank of America (NYSE:BAC). Your line is open
Q – Jason Zemansky: Thank you. Good morning, team. Congrats on the quarter and thanks for taking our questions. I apologize if I missed this, but to what extent did stocking and inventory build contributed to the quarter's total? And then a follow-up, if I may.
Eric Warren: That's a short answer, Jason. It was none. No effect on quarterly revenue.
Q – Jason Zemansky: Got it. Perfect. And then what should we be thinking about gross to net trends, as you start to bring more payers online especially, given the sizable patient population in primary prevention?
Eric Warren: Yes, I can take that one also. So as far as gross to net goes for the year, we expect it to follow the same cyclicality that we've seen in prior years. And as a reminder Q1, is our best quarter in Q4 is our worse. So it gets progressively worse of the year, largely driven by the Medicare coverage gap. As far as the actual percentage year-over-year, I would say, it's going to be consistent the payers updating towards the UM criteria and adding that primary prevention, doesn't necessarily change the rebate or any the amount paid to them. It's just the indication covered. So as far as the actual gross to net number, we don't really see that changing materially year-over-year. Just it will follow the same cyclicality, that it does every year.
Q – Jason Zemansky: Got it. I guess, I was looking for more color as to whether or not, payers were looking for more concessions, again, given kind of the sizable shift in overall population I guess overall moving forward.
Sheldon Koenig: I can take that Jason. I mean, we've been very pleased as Eric mentioned with our interactions with our payers. And the short answer to that is also, no. So and I think part of it is, just based upon the alignment that we gained, when we presented the data at ACC and went to them immediately. This is something that they've been prepared for. But there has not been a meaningful request, as it relates to what our new label update is, the best answer I can give you.
Q – Jason Zemansky: Got it. Okay. Perfect. Thank you so much for the color.
Operator: Thank you. Ladies and gentlemen, I'm showing no further questions in the queue. I would now like to turn the call back over to Sheldon for his closing remarks.
Sheldon Koenig: Great. Thank you, Towanda. Thank you, everyone, again for your time and interest today. Again, we couldn't be more pleased, with our first quarter performance. Our label approval and for what they mean for millions of primary and secondary prevention patients, who are unable to achieve their LDL-cholesterol goals, with current therapies alone. We look forward to continuing to execute on our commercial plan and keep posted on our progress in the weeks and months ahead. Look for us at the hostesses conferences, in the upcoming weeks. We have a real busy May in front of us. Take care, and see all of you soon. Thank you, again.
Operator: Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.